MedTrace Logo

A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension

NCT06671392 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2026-03-19

No results posted yet for this study

Summary

A Multi-center, Randomized, Double-blind, Parallel design, Phase III study to Evaluate and Compare the Efficacy and Safety of DWC202405/DWC202313 and DWC202314 Combination Therapy to DWC202405/DWC202313 in Patients with Essential Hypertension Inadequately Controlled with DWC202405

Conditions

  • Essential Hypertension

Interventions

DRUG

DWC202405

5/20mg, 1 tablet, Oral, Once a day

DRUG

DWC202405, DWC202314

5/20mg + 1.5mg, 1 tablet, Oral, Once a day

DRUG

DWC202405, DWC202314P

5/20mg + 1.5mg, 1 tablet, Oral, Once a day

DRUG

DWC202313, DWC202314

10/40mg + 1.5mg, 1 tablet, Oral, Once a day

DRUG

DWC202313, DWC202314P

10/40mg + 1.5mg, 1 tablet, Oral, Once a day

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-24
Primary Completion
2026-02-05
Completion
2026-02-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06671392 on ClinicalTrials.gov